Author: Daily Vitamins / Category: Uncategorized
Ginkgo biloba
Treatments:
Age-related cognitive decline (ARCD) Alzheimer’s disease (early-stage) Glaucoma (normal tension glaucoma) Intermittent claudication Altitude sickness (prevention) Depression (for elderly people) Erectile dysfunction (of vascular origin) Macular degeneration Schizophrenia (in combination with haloperidol) Vertigo Vitiligo Asthma Atherosclerosis Deafness, acute cochlear Memory enhancement (in healthy adults) Ménière’s disease Migraine headaches Multiple sclerosis (injections) Premenstrual syndrome Raynaud’s disease Retinopathy Tinnitus Type 1 diabetes Type 2 diabetes
Common Symptoms:
Dosages:
Most clinical trials have used between 120 and 240 mg of ginkgo (standardized to contain 6% terpene lactones and 24% flavone glycosides) per day, generally divided into two or three portions. The higher amount (240 mg per day) has been used in some people with mild-to-moderate Alzheimer’s disease, age-related cognitive decline, intermittent claudication, and resistant depression. Ginkgo may need to be taken for eight to twelve weeks before desired actions such as cognitive improvement are noticed. Although nonstandardized Ginkgo biloba leaf and tinctures are available, there is no well-established amount or use for these forms.
Side Effects:
Excessive bleeding has been reported in a few individuals taking ginkgo, although a cause/effect relationship was not proven. In addition, two elderly individuals with well-controlled epilepsy developed recurrent seizures within two weeks after starting ginkgo. Mild headaches lasting for a day or two and mild upset stomach have been reported in a small number of people using ginkgo. Ginkgo leaves are known to contain a group of potentially toxic constituents known as alkylphenols. To reduce the potential for adverse effects, the German Commission E Monograph requires that ginkgo products for human consumption contain less than 5 parts per million of alkylphenols. One small clinical trial found that ginkgo supplementation for three months increased secretion of insulin by the pancreas, but did not affect blood glucose levels, in healthy young adults. These results suggest that the participants may have developed an insensitivity to insulin, a potential concern because insulin insensitivity may be a precursor to type 2 diabetes. However, this trial does not prove that ginkgo causes insulin insensitivity, nor does it prove that long-term ginkgo supplementation increases the risk for any disease. In addition, the results of this trial are not consistent with other research on ginkgo. Larger and more rigorously designed clinical trials of ginkgo supplementation have found no significant adverse effects after as many as 12 months of supplementation. People should seek an accurate medical diagnosis prior to self-prescribing ginkgo. This is especially important for the elderly, whose circulatory conditions can involve serious disease, and for people scheduled for surgery, as ginkgo may affect bleeding time. Certain medicines may interact with Ginkgo biloba. Refer to drug interactions for a list of those medicines.
